Patrick Campbell

With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete stabilization of transthyretin (TTR).

New research reveals that elevated lipoprotein(a) and oxidized phospholipids are independent risk factors for early-stage heart failure progression.

An analysis study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.

A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.

A study from investigators in Italy sheds further light on the relationship between physical activity and diabetic polyneuropathy risk in patients with type 1 diabetes.

Recor Medical announced the FDA approval of its Paradise Ultrasound Renal Denervation system for the treatment of hypertension on November 7, 2023.

Data from a 4-year trial of preschool-aged children offers new insight into the effects of initiating obesity management strategies among children in early life.

At ERS International Congress 2023, new data related to use of sotatercept offered providers additional insight into the effects of the agent in people with pulmonary arterial hypertension (PAH).

Patients with heart failure with preserved ejection fraction (HFpEF) may experience worsened exercise tolerance if they also have anemia.

A study from UCSD highlights how advances in imaging modalities and utilization could aid in the early detection of psoriatic arthritis.

In their latest recommendation statement, the US Preventive Services Task Force (USPSTF) recommends blood pressure screening for all pregnant individuals to detect hypertensive disorders.

Elevated serum endotrophin levels, but not urinary endotrophin levels, predict increased risk of kidney complications and mortality in type 1 diabetes.

An analysis of electronic health record data recorded from 2018-2022 within Duke University Medical Center–affiliated diabetes care centers suggests the increased rate of new-onset type 1 and type 2 diabetes observed during the first year of the pandemic persisted through 2022.

Noortje van Herwaarden, MD, PhD, discusses the results of a 10-year follow-up from the DRESS study and how it informs use of disease activity-guided dose optimization in treatment of rheumatoid arthritis.

An analysis of Medicaid data from adults in Alabama suggests just more than 50% of patients fail to get ambulatory follow-up care within the recommended 14-day window following a first-time heart failure hospitalization.

Just over a year since AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular (CV) death and heart failure–related hospitalizations for dapagliflozin (Farxiga) based on results of the phase 3 DELIVER trial.

An analysis of more than 500,000 pregnancies over a 15-year period suggests much of the increase in gestational diabetes rates observed during the study period can be attributed to changes in screening practices.

A systematic review and meta-analysis presented at ACR Convergence 2022 provide insight into the effects of belimumab in patient populations with cutaneous lupus erythematosus, with or without systemic lupus erythematosus (SLE).

Results indicate early initiation of tumor necrosis factor (TNF) inhibitors in a veterans population was associated with a 17% increase in incident cardiovascular disease and a 22% increase in major events.